Research and development expenses for the second quarter of 2013 were $6.5 million, as compared to $8.7 million for the comparable quarter in 2012. For the six months ended June 30, 2013, research and development expenses were $15.1 million, as compared to $16.5 million for the same period in 2012.
Research and development expenses primarily relate to the following Dyax research and development initiatives: 1) KALBITOR medical support and post-marketing requirements; 2) development of a single-injection formulation of KALBITOR; 3) development costs associated with DX-2930, a fully human monoclonal antibody inhibitor of plasma kallikrein; and 4) pass-through license fees paid by Dyax licensees under the LFRP.
Selling, general and administrative expenses were $10.2 million for the second quarter of 2013, as compared to $10.4 million for the comparable quarter in 2012. For the six months ended June 30, 2013, selling, general and administrative costs were $21.3 million, as compared to $20.8 million for the same period in 2012.
For the quarter ended June 30, 2013, Dyax reported a net loss of $8.4 million or $0.08 per share attributable to common stockholders, as compared to a net loss of $7.9 million or $0.08 per share for the comparable quarter in 2012. For the six months ended June 30, 2013, Dyax reported a net loss of $19.6 million or $0.19 per share attributable to common stockholders, as compared to a net loss of $19.2 million or $0.19 per share for the comparable period in 2012.As of June 30, 2013, Dyax had cash, cash equivalents, and investments totaling $46.9 million, exclusive of restricted cash. Financial Guidance Dyax’s has reiterated its financial guidance for 2013:
Top-line total revenue to be in the range of $53-58 million, including
- KALBITOR net sales in the range of $40-44 million.
|Date:||Wednesday, July 24, 2013|
|Time:||5:00 p.m. ET|
|Telephone Access:||Domestic callers, dial 877-674-2415; reference the Dyax conference call|
|International callers, dial 708-290-1364|
|No passcode required.|
|Online Access:||Go to the Investor Relations section of the Dyax website ( www.dyax.com) and follow instructions for accessing the live webcast. Participants may register in advance.|
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV